Finished product reference
Troxerutin
Tablet, Effervescent · Oral · 1000 mg
- List code
- 52521
- Pharmacologic class
- Vasoprotective agent (flavonoid; hydroxyethylrutoside)
What it is and how it works
Troxerutin is a semi-synthetic hydroxyethylated derivative of rutin. It reduces capillary permeability and fragility, decreases oedema formation, and has antioxidant and mild anti-inflammatory effects on the venous wall and microcirculation.
Indications
Symptomatic relief of chronic venous insufficiency (heaviness, pain, oedema, cramps of the legs), varicose veins and haemorrhoids.
Dosage and administration (summary)
Orally, typically 300 mg two to three times daily with meals, reduced for maintenance according to response.
Contraindications
Hypersensitivity to troxerutin or other rutosides.
Warnings and precautions
It relieves symptoms but does not replace compression therapy or treatment of underlying venous disease; persistent or worsening symptoms, or signs of thrombosis, require medical evaluation. Gastrointestinal upset, headache and flushing may occur.
Pregnancy
Avoid in the first trimester; use later in pregnancy only if clearly needed.
Storage and supply
Store below 25 °C, protected from moisture.
Source: reference summary prepared from the EU SmPC/EPAR, BNF and WHO Model Formulary. The approved product information in Iran governs.
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.